Patients with private insurance were more likely to receive HER2-targeted therapy compared to the uninsured, which is in line with previous studies that suggest insurance coverage plays a pivotal role in access to advanced cancer treatments [23,24]. The gene discussed is ERBB2; the disease is cancer.